AHA reiterates support for most-favored nation drug price rule’s withdrawal
The AHA today restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule. In January, the AHA questioned the proposal’s legality and structure, while expressing deep concerns for the extent to which patients would be negatively impacted by the policy.
Related News Articles
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The government shutdown is expected to continue into next week as the Senate is expected to adjourn Oct. 23 with no plans to vote this weekend. The chamber Oct…
Headline
The Senate Oct. 16 failed for a 10th time to advance the continuing resolution to extend government funding and end the ongoing shutdown. The chamber adjourned…
Chairperson's File
There is a saying that is very timely for our field: A smooth sea never made a skilled sailor. As we head into the final months of 2025, hospitals and health…
Headline
The federal government shutdown is expected to continue into next week as the Senate adjourned Oct. 9 after failing to pass spending legislation; senators plan…
Headline
The AHA provided a statement of record to the Senate Special Committee on Aging for a hearing Oct. 8 on the pharmaceutical and medical device supply chains.…